Speeding up the delivery of Alzheimer’s & Parkinson’s Disease Treatments
GAP and our over 100 clinical research partners (GAP-Net Sites) around the world are collaborating to speed the delivery of Alzheimer’s and Parkinson’s disease treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and duration of clinical trials to ensure that no one is left behind.
Nearly 7 Million
Americans are currently living with Alzheimer’s disease.
141%
Increase in deaths from Alzheimer’s between 2000 and 2021.
$360 Billion
The estimated cost of treating Alzheimer’s in the United States in 2024.
Our Global Network
GAP-Net includes leading private and academic research sites across North America and Europe, connecting neurodegenerative trials to researchers, and researchers to participants with our flagship services, including GAP Participant Services (GPS Liaisons) and our Inclusive Research Initiative (Community Connectors).
Learn moreInformation About Our Global Network
GPS Liaisons and Community Connectors providing high-touch support and resources
GPS visits since 2019, helping bridge sites, community-based organizations, studies and volunteers
GAP-Net sites in North America and Europe/United Kingdom
Since 2018, GAP has
successfully...
Supported
15+
GAP-Enabled trials
Initiated
4
GAP-Sponsored studies
